**Proteins** 

## **Product** Data Sheet

## Gevokizumab

Cat. No.: HY-P99171 CAS No.: 1129435-60-4

Target: Interleukin Related

Pathway: Immunology/Inflammation

**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.

## **BIOLOGICAL ACTIVITY**

Description	Gevokizumab is a potent anti-IL-1 $\beta$ antibody, negatively modulates IL-1 $\beta$ signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1 $\beta$ for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) <sup>[1][2]</sup> .	
In Vitro	Gevokizumab (5 nM; 16 h) shows inhibitory effects of IL-1 $\beta$ -mediated NF-kB activation caused by the soluble receptors, sIL-1RI and sIL-1RII in HeLa cells <sup>[1]</sup> . Gevokizumab (1.85, 5.55, 16.66, and 50 nM) is a selective negative allosteric modulator which reduces the binding affinity of sIL-1RI to IL-1 $\beta$ <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation <sup>[2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Rat carotid denudation model in Sprague-Dawley rats (3-month0-old, 330-360 g) <sup>[2]</sup>
	Dosage:	1, 10 and 50 mg/kg
	Administration:	Intravenous injection; once daily for 3 days
	Result:	Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg.

## **REFERENCES**

[1]. Issafras H, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1 $\beta$  antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014 Jan;348(1):202-15.

[2]. Roubille F, et al. The interleukin- $1\beta$  modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis. 2014 Oct;236(2):277-85.

Page 1 of 2 www.MedChemExpress.com

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com